ES2163795T3 - Composicion farmaceutica contra los tumores e infecciones por papilomavirus. - Google Patents

Composicion farmaceutica contra los tumores e infecciones por papilomavirus.

Info

Publication number
ES2163795T3
ES2163795T3 ES97935646T ES97935646T ES2163795T3 ES 2163795 T3 ES2163795 T3 ES 2163795T3 ES 97935646 T ES97935646 T ES 97935646T ES 97935646 T ES97935646 T ES 97935646T ES 2163795 T3 ES2163795 T3 ES 2163795T3
Authority
ES
Spain
Prior art keywords
papilomavirus
polypeptide
pharmaceutical composition
infections
composition against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97935646T
Other languages
English (en)
Other versions
ES2163795T5 (es
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie-Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2163795(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of ES2163795T3 publication Critical patent/ES2163795T3/es
Publication of ES2163795T5 publication Critical patent/ES2163795T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA DESTINADA AL TRATAMIENTO O PREVENCION DE UNA INFECCION O UN TUMOR POR PAPILOMAVIRUS QUE COMPRENDE, COMO AGENTES TERAPEUTICOS, UN POLIPEPTIDO OIGINARIO DE UNA REGION PRECOZ Y UN POLIPEPTIDO OIGINARIO DE UNA REGION TARDIA DE UN PAPILOMAVIRUS, EVENTUALMENTE ASOCIADOS A UN POLIPEPTIDO CON ACTIVIDAD INMUNOESTIMULANTE, O UN POLIPEPTIDO OIGINARIO DE UNA REGION PRECOZ O TARDIA DE UN PAPILOMAVIRUS Y UN POLIPEPTIDO CON ACTIVIDAD INMUNOESTIMULANTE O, DE FORMA ALTERNATIVA, UN VECTOR RECOMBINANTE EN EL QUE SE HAN INSERTADO LOS FRAGMENTOS DE ADN CODIFICANTES PARA LAS COMBINACIONES DE POLIPEPTIDOS ANTES MENCIONADAS.
ES97935646T 1996-07-30 1997-07-29 Composicion farmaceutica contra los tumores e infecciones por papilomavirus. Expired - Lifetime ES2163795T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609584 1996-07-30
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (2)

Publication Number Publication Date
ES2163795T3 true ES2163795T3 (es) 2002-02-01
ES2163795T5 ES2163795T5 (es) 2006-07-16

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97935646T Expired - Lifetime ES2163795T5 (es) 1996-07-30 1997-07-29 Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
ES01109013T Expired - Lifetime ES2215805T3 (es) 1996-07-30 1997-07-29 Composicion farmaceutica para el tratamiento de los tumores e infecciones por papilomavirus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01109013T Expired - Lifetime ES2215805T3 (es) 1996-07-30 1997-07-29 Composicion farmaceutica para el tratamiento de los tumores e infecciones por papilomavirus.

Country Status (12)

Country Link
EP (2) EP0862634B2 (es)
JP (2) JP4070815B2 (es)
AT (2) ATE265535T1 (es)
AU (1) AU736720B2 (es)
CA (1) CA2234263C (es)
DE (2) DE69706825T3 (es)
DK (2) DK1149910T3 (es)
ES (2) ES2163795T5 (es)
FR (1) FR2751879B1 (es)
HK (1) HK1043809B (es)
PT (2) PT1149910E (es)
WO (1) WO1998004705A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
CA2335506A1 (en) * 1998-06-26 2000-01-06 Aventis Pasteur Mucosal targeting immunisation
RU2489486C2 (ru) 2006-06-20 2013-08-10 Трансжене С.А. Процесс получения поксвирусов и композиции поксвирусов
EP2382474B1 (en) 2009-01-20 2015-03-04 Transgene SA Soluble icam-1 as biomarker for prediction of therapeutic response
WO2010108908A1 (en) 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
NZ594896A (en) 2009-04-17 2013-07-26 Transgene Sa Biomarker for monitoring patients
US8445270B2 (en) 2009-05-12 2013-05-21 Transgene S.A. Immortalized avian cell lines and use thereof
RU2552292C2 (ru) 2009-07-10 2015-06-10 Трансжене Са Биомаркер для отбора пациентов и связанные с ним способы
IN2012DN01577A (es) 2009-07-21 2015-06-05 Transgene Sa
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
JP6655618B2 (ja) 2014-12-01 2020-02-26 トランジェーヌＴｒａｎｓｇｅｎｅ 安定な液体ワクシニアウイルス処方物
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
JP2020519666A (ja) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定性のウイルス含有組成物
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
AU2021233167A1 (en) 2020-03-12 2022-09-22 Bavarian Nordic A/S Compositions improving poxvirus stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
CA2038581A1 (en) † 1990-03-20 1991-09-21 Martin Muller Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
US7476389B1 (en) * 1991-07-19 2009-01-13 The University Of Queensland Papillomavirus vaccines
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
WO1998004705A1 (fr) 1998-02-05
HK1043809A1 (en) 2002-09-27
DK0862634T3 (da) 2002-01-21
FR2751879B1 (fr) 1998-10-30
EP0862634B1 (fr) 2001-09-19
HK1043809B (zh) 2004-12-03
DK1149910T3 (da) 2004-08-02
DK0862634T4 (da) 2006-05-08
DE69728914D1 (de) 2004-06-03
ES2163795T5 (es) 2006-07-16
JP4198735B2 (ja) 2008-12-17
ATE205881T1 (de) 2001-10-15
CA2234263C (fr) 2009-10-13
PT862634E (pt) 2002-03-28
JP2000500662A (ja) 2000-01-25
DE69728914T2 (de) 2005-04-07
JP4070815B2 (ja) 2008-04-02
DE69706825T3 (de) 2006-08-24
CA2234263A1 (fr) 1998-02-05
AU736720B2 (en) 2001-08-02
EP0862634A1 (fr) 1998-09-09
EP0862634B2 (fr) 2006-03-01
DE69706825T2 (de) 2002-05-02
ATE265535T1 (de) 2004-05-15
EP1149910A1 (fr) 2001-10-31
EP1149910B1 (fr) 2004-04-28
JP2007254474A (ja) 2007-10-04
FR2751879A1 (fr) 1998-02-06
DE69706825D1 (de) 2001-10-25
ES2215805T3 (es) 2004-10-16
PT1149910E (pt) 2004-09-30
AU3855297A (en) 1998-02-20

Similar Documents

Publication Publication Date Title
ES2163795T3 (es) Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
AR032293A1 (es) Estuche farmaceutico
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
EA200100764A1 (ru) Трициклические ингибиторы поли(adp-рибозо) полимераз
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
DE69931766D1 (de) Antitumorale mittel
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ES2194720T3 (es) Enzimas para el tratamiento de diabetes mellitus tipo i.
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
ES2167365T3 (es) Vectores adenovirales de origen animal y utilizacion en terapia genica.
CU23367A3 (es) Formulación de moxifloxacino con sal común
ES2058898T3 (es) Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus.
BR9811094A (pt) Agente terapêutico para tumores linfáticos
TR200003443T2 (tr) Geçmeyen depresyonun tedavisi için kombinasyon terapisi
HN2000000050A (es) Sal mutua de amlodipino y atorvastatina
BR9814299A (pt) Aminobiguanidas e o seu uso para desinfetarlentes de contato e preservar composiçõesfarmacêuticas
TR199901104T2 (xx) Farmas�tik bile�ikler.
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
BR0016831A (pt) Composição terapêutica e lente de contato impregnada pela mesma
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR9810981A (pt) Medicamento contendo ioimbina e arginina para tratamento de disfunção erétil
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
GT199900171A (es) Concentrado oral de sertralina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 862634

Country of ref document: ES